• Explore /
  • Poster
  • / A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).

A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).

Abstract Poster

Authors

Toni Choueiri

Toni K. Choueiri

Dana-Farber Cancer Institute, Boston, MA

Toni K. Choueiri , Andrea B. Apolo , Thomas Powles , Bernard Escudier , Osvaldo Rudy Aren , Amishi Shah , Elizabeth Riley Kessler , James J Hsieh , Joshua Zhang , Burcin Simsek , Christian Scheffold , Robert J. Motzer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03141177

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS4598)

DOI

10.1200/JCO.2018.36.15_suppl.TPS4598

Abstract #

TPS4598

Poster Bd #

418a

Abstract Disclosures

Similar Posters

First Author: Nizar M. Tannir

First Author: Nizar M. Tannir

First Author: Tian Zhang

First Author: Robert J. Motzer